Low-debt companies can attract investors because they typically have stronger balance sheets, lower interest costs and greater financial flexibility. They may also be better positioned to fund expansion, invest in technology and weather economic slowdowns without relying heavily on external borrowing.
However, a premium valuation reflects high market expectations for future earnings growth, profitability and competitive advantages. Investors must therefore assess whether a company's growth prospects justify the price its shares command.
This article examines five low-debt stocks trading at premium valuations. This is not a stock recommendation.
Divi's Laboratories is one of India's leading pharmaceutical manufacturers, supplying active pharmaceutical ingredients (APIs), intermediates and custom synthesis products to global pharmaceutical companies.
The company has a debt-to-equity ratio of zero, giving it a debt-free balance sheet and reducing its exposure to interest costs. However, its valuation multiples are significantly higher than those of the broader healthcare sector.